Compare Johnson & Johnson (JNJ) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Marvell Technology Inc — how do they compare? Johnson & Johnson trades at $250.33 (market cap $598.96B), while Marvell Technology Inc trades at $206.26 (market cap $171.11B). The key difference: Johnson & Johnson is far larger — about 3.5× Marvell Technology Inc's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | MRVL | |
|---|---|---|
Market Cap | $598.96B | $171.11B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $316.43 |
52-Week Low | $164.36 | $62.31 |
Enterprise Value | $631.90B | $172.55B |
Dividend Yield | 2.15% | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Marvell Technology (MRVL) trades at $195.28, up 3.5% today, with a bullish technical signal from oscillators but bearish moving averages. Recent earnings have consistently beaten expectations, though the company reported a net loss of $885 million in 2025. Analyst consensus is strongly bullish with an average price target of $275.68, and the stock is positioned in the AI infrastructure sector, with news highlighting its potential in custom chips and networking.
Outlook is positive due to strong analyst support and AI-driven growth prospects, but risks include high valuation multiples, recent net losses, and semiconductor market volatility. The stock offers significant upside if execution matches expectations, yet investors must weigh growth potential against current profitability challenges and industry cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
